Cargando…
IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy
Isocitrate dehydrogenase 1 and 2 (IDH1/2) are enzymes recurrently mutated in various types of cancer, including glioma, cholangiocarcinoma, chondrosarcoma, and acute myeloid leukemia. Mutant IDH1/2 induce a block in differentiation and thereby contribute to the stemness and oncogenesis of their cell...
Autores principales: | Molenaar, Remco J., Wilmink, Johanna W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721574/ https://www.ncbi.nlm.nih.gov/pubmed/34967233 http://dx.doi.org/10.1369/00221554211062499 |
Ejemplares similares
-
Wild-type and mutated IDH1/2 enzymes and therapy responses
por: Molenaar, Remco J., et al.
Publicado: (2018) -
Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses
por: Molenaar, Remco J., et al.
Publicado: (2018) -
IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018) -
Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1-Mutated Cancer Cells
por: Khurshed, Mohammed, et al.
Publicado: (2022) -
Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
por: van Noorden, Cornelis J.F., et al.
Publicado: (2021)